Though highly effective, medications for the prevention of chronic kidney disease progression are under-utilized, emphasizing the need for better use of prognostic tools.

Examples of selflessness are hard to find in today’s world.However, there are still some people in the world who think of ...

Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 HORIZON Study of MZE829, ...

The study reveals new evidence that reinforces the health consequences of exposure. Researchers identify troubling cause of ...